ovarian hyperstimulation syndromes การใช้

• But ovarian hyperstimulation syndrome may not be so rare.
• Ovarian hyperstimulation syndrome ( OHSS ) occurs in 5-10 % of cases.
• Rare adverse events ( < 1 % of people ) include : baldness and / or ovarian hyperstimulation syndrome.
• This is a minimally invasive procedure, but it does carry some health risks, such as ovarian hyperstimulation syndrome.
• Some patients with ovarian hyperstimulation syndrome may have mutations in the gene for FSHR, making them more sensitive to gonadotropin stimulation.
• There is no evidence for an increased risk of ovarian hyperstimulation syndrome ( OHSS ) with IVF when compared with ovarian stimulation combined with IUI.
• Findings are conflicting, but metformin treatment as a complement in IVF cycles may reduce the risk of ovarian hyperstimulation syndrome and increase live birth rates.
• Induction of final maturation ( such as done with hCG ) may need to be withheld because of increased risk of ovarian hyperstimulation syndrome ( OHSS ).
• On the other hand, the GnRH antagonist protocol has a lower risk of ovarian hyperstimulation syndrome ( OHSS ), which is a life-threatening complication.
• In cycles followed by oocyte donation, use of GnRH agonists instead of hCG decreases the risk of ovarian hyperstimulation syndrome with no evidence of a difference in live birth rate.
• In fresh ( rather than " in vitro " fertilization, final oocyte maturation triggering with GnRH agonist instead of hCG decreases the risk of ovarian hyperstimulation syndrome but decreases live birth rate.
• A small number of underpowered randomized trials came to the result that use of clomifene in addition to gonadotropins results in similar live birth rate but with a reduction in the incidence of ovarian hyperstimulation syndrome.
• "Coasting ", which is ovarian hyperstimulation without induction of final maturation, does not significantly decrease the risk of ovarian hyperstimulation syndrome ( OHSS ), according to a Cochrane review of randomized trials.
• Using a GnRH agonist instead of hCG for inducing final oocyte maturation and / or release results in an elimination of the risk of ovarian hyperstimulation syndrome, but a slight decrease of the delivery rate of approximately 6 %.
• Less common causes include esophageal rupture or pancreatic disease, intra-abdominal abscesses, rheumatoid arthritis, asbestos pleural effusion, mesothelioma, Meigs'syndrome ( ascites and pleural effusion due to a benign ovarian tumor ), and ovarian hyperstimulation syndrome.
• Additionally, a systematic review and meta-analysis concluded that prophylactic treatment with cabergoline reduces the incidence, but not the severity, of ovarian hyperstimulation syndrome ( OHSS ), without compromising pregnancy outcomes, in females undergoing stimulated cycles of in vitro fertilization ( IVF ).
• Final maturation induction using a GnRH agonist is recommended in women with cancer undergoing fertility preservation, because ovarian hyperstimulation syndrome is associated with an increased risk of arterial thrombotic events such as stroke, myocardial infarction and peripheral arterial embolism, and this risk can add to an already increased risk caused by the cancer.